JP2024509193A5 - - Google Patents

Info

Publication number
JP2024509193A5
JP2024509193A5 JP2023553584A JP2023553584A JP2024509193A5 JP 2024509193 A5 JP2024509193 A5 JP 2024509193A5 JP 2023553584 A JP2023553584 A JP 2023553584A JP 2023553584 A JP2023553584 A JP 2023553584A JP 2024509193 A5 JP2024509193 A5 JP 2024509193A5
Authority
JP
Japan
Prior art keywords
triethylenetetramine
manufactured article
approximately
dicuccinate
article according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023553584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/019025 external-priority patent/WO2022187709A1/en
Publication of JP2024509193A publication Critical patent/JP2024509193A/ja
Publication of JP2024509193A5 publication Critical patent/JP2024509193A5/ja
Pending legal-status Critical Current

Links

JP2023553584A 2021-03-05 2022-03-04 銅障害の処置 Pending JP2024509193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163157539P 2021-03-05 2021-03-05
US63/157,539 2021-03-05
PCT/US2022/019025 WO2022187709A1 (en) 2021-03-05 2022-03-04 Treatment of copper disorders

Publications (2)

Publication Number Publication Date
JP2024509193A JP2024509193A (ja) 2024-02-29
JP2024509193A5 true JP2024509193A5 (https=) 2025-01-24

Family

ID=83115853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023553584A Pending JP2024509193A (ja) 2021-03-05 2022-03-04 銅障害の処置

Country Status (7)

Country Link
US (2) US20220280451A1 (https=)
EP (1) EP4301350A4 (https=)
JP (1) JP2024509193A (https=)
CN (1) CN117157064A (https=)
AU (1) AU2022231038A1 (https=)
CA (1) CA3212016A1 (https=)
WO (1) WO2022187709A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023255339A1 (en) * 2022-04-19 2024-12-05 Sasha A. PHILBERT Treatment of brain copper disorders
CN118987254A (zh) * 2024-08-15 2024-11-22 沈阳药科大学 一种基于双金属纳米点-溶瘤病毒静脉递送系统及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875522A1 (en) * 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
PT1778618E (pt) * 2004-07-19 2014-03-04 Philera New Zealand Ltd Síntese de trietilenotetraminas
WO2006104396A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Pre-complexed copper antagonist compositions
CA3018698A1 (en) * 2005-11-09 2007-05-18 Philera New Zealand Limited Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
US20090093542A1 (en) * 2007-10-04 2009-04-09 Cooper Garth J S Copper antagonist compositions
WO2017049529A1 (en) * 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
WO2017213524A1 (en) * 2016-06-10 2017-12-14 Garth Cooper Treatment of neurodegenerative disorders
CA3143523A1 (en) * 2019-06-17 2020-12-24 Philera New Zealand Ltd. Combination treatments for central nervous system disorders

Similar Documents

Publication Publication Date Title
JP4108980B2 (ja) 持続放出ラノラジン製剤
US10159658B2 (en) Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2273985B1 (en) Capsule for the prevention of cardiovascular diseases
JP2008069159A5 (https=)
RU2016125229A (ru) Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
TW200948354A (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
JP2023552700A5 (https=)
WO2014011926A1 (en) Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2024509193A5 (https=)
US20230346817A1 (en) Composition and use of sglt-2 inhibitor and angiotensin receptor blockers
CN105338970B (zh) 包含他达拉非和坦洛新的药物胶囊复合制剂
WO2021129735A1 (zh) 一种固体制剂及其制备方法和用途
CN101642444B (zh) 单硝酸异山梨酯双速渗透泵型控释制剂及其制备方法
CN101642443B (zh) 单硝酸异山梨酯渗透泵型控释制剂及其制备方法
CN112402392A (zh) 一种甲磺酸达比加群酯缓释制剂及其制备方法
US11648240B2 (en) Pharmaceutical composition comprising famotidine, lidocaine and melatonin
EP0413694B1 (fr) Preparations medicamenteuses cardio-protectrices comprenant l'amiodarone, un derive nitre, notamment le dinitrate d'isosorbide et facultativement un beta-bloqueur
WO2023208241A1 (zh) 一种吡非尼酮持续性释放口服固体制剂
EP1465607B1 (fr) Compositions pharmaceutiques a liberation modifiee
US20200061053A1 (en) Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
TR2022007384A2 (tr) Anti̇vi̇ral etken madde i̇hti̇va eden kati dozaj formlari
US20170326065A1 (en) Methods and composition for treatment of cardiovascular conditions
TR2023007202A1 (tr) Saksagli̇pti̇n, pi̇ogli̇tazon ve bi̇r sglt-2 i̇nhi̇bi̇törü i̇çeren bi̇r farmasöti̇k formülasyon
TR2023007201A1 (tr) Vi̇ldagli̇pti̇n, metformi̇n ve bi̇r sglt-2 i̇nhi̇bi̇törü i̇çeren bi̇r farmasöti̇k formülasyon
TR2022007368A2 (tr) Anti̇vi̇ral kompozi̇syonlar